Overview
Overview
L-Carnitine is an amino acid derivative essential for fatty acid transport into mitochondria, where it facilitates β-oxidation and energy production[1]. Subcutaneous administration bypasses intestinal conversion to trimethylamine-N-oxide (TMAO), a metabolite associated with cardiovascular concerns[4], while providing 100% bioavailability compared to 5–18% for large oral doses[3]. This educational protocol presents a once-daily subcutaneous approach optimized for insulin-syringe measurements. Re
- Category
- Weight Loss
- Routes
- subcutaneous
Mechanism
L-Carnitine
Mechanism of action
Mechanism of action
L-Carnitine is a quaternary ammonium compound biosynthesized from lysine and methionine that plays a critical role in energy metabolism. It acts as an obligate cofactor for the carnitine palmitoyltransferase (CPT) enzyme system, which shuttles long-chain fatty acids across the inner mitochondrial membrane for β-oxidation [1] . This process is essential for ATP production from fat stores, particularly during prolonged exercise or caloric restriction. Clinical and preclinical studies indicate L-Carnitine supplementation can enhance fat oxidation, reduce body weight, and improve exercise performance in certain populations [2] [5] . A meta-analysis of 37 randomized controlled trials found approximately 2,000 mg/day oral L-Carnitine yields modest weight-loss effects (~1.2 kg), with diminishing returns above that dose [2] . Why subcutaneous over oral? Oral L-Carnitine has poor bioavailability (5–18% at high doses) due to saturable intestinal absorption [3] . Furthermore, unabsorbed carnitine is metabolized by gut bacteria into trimethylamine (TMA), which is converted to trimethylamine-N-oxide (TMAO) in the liver—a metabolite linked to increased cardiovascular risk [4] [9] . Subcutaneous or intravenous administration provides 100% bioavailability and bypasses TMAO production, as demonstrated in animal models where parenteral L-Carnitine did not promote atherosclerosis unlike oral dosing [4] . In hemodialysis patients with carnitine deficiency, intravenous L-Carnitine (10–40 mg/kg after dialysis sessions) significantly increased plasma carnitine levels, reduced fatigue, and preserved exercise capacity over 24 weeks with excellent tolerability [5] . High-dose intravenous protocols (up to 50 mg/kg daily, ~3,500 mg for a 70 kg person) have been used safely in patients with metabolic disorders [8] , indicating a wide therapeutic margin.
Key research findings
- 01
L-Carnitine is a naturally occurring amino-acid-derived quaternary ammonium compound essential for transporting long-chain fatty acids into mitochondria for beta-oxidation via the carnitine shuttle (established biochemistry / human physiology).
- 02
Human studies of oral L-carnitine intake on body weight and fat mass show small and inconsistent effects; meta-analyses report modest average differences that are heterogeneous across populations (human studies, mixed).
- 03
Carnitine status is physiologically relevant in specific deficiency states and certain populations, where it has an established role (human physiology).
- 04
Several research forms are studied, including L-carnitine, acetyl-L-carnitine, L-carnitine L-tartrate, and propionyl-L-carnitine, which differ in pharmacokinetics and research use (mechanistic).
- 05
Exercise-performance and recovery research shows variable results depending on form, dose, and study design (human studies, mixed).
Primary source: L-Carnitine has a large, long-standing human and preclinical literature on fatty-acid metabolism, but evidence specific to weight or fat loss in non-deficient individuals is mixed and generally modest, so strong conclusions are not warranted.
Protocol Reference
Protocol reference
Commonly cited research range: 50–100 mg, daily.
Reference figures reported in the research literature — not a dosing recommendation. For interactive vial math and scheduling, see the Calculator and Schedule tabs.
Cited protocol & reconstitution guide
Source-backed reference fields by phase, including any volume fields authored in the cited guide.
Weeks 1–2
50 mg
Weeks 3–8
100 mg
Weeks 9–12
100 mg
| Phase | Reference amount | Units / volume |
|---|---|---|
| Weeks 1–2 | 50 mg | 50 units (0.50 mL) |
| Weeks 3–8 | 100 mg | 100 units (1.0 mL) |
| Weeks 9–12 | 100 mg | 100 units (1.0 mL) |
Storage & Handling
Storage requirements(typical for most peptides)
Can be stored for extended periods. Protect from moisture.
Store in refrigerator door. Never freeze after reconstitution.
Label vials with reconstitution date. Discard if cloudy.
Reconstitution steps
- 01🌡️Draw 2.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- 02🧴Inject slowly down the vial wall to minimize foaming; avoid direct stream onto powder.
- 03💉Gently swirl or roll the vial until powder is fully dissolved (do not shake vigorously).
- 04💧Label vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- 05🔄Use within 2–4 weeks; bacteriostatic water preservative inhibits microbial growth during multi-dose use[6].
- 06🏷️Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional storage notes
Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure. Keep vial tightly sealed. Stable for months to years when frozen [13] .
Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing. Do not freeze reconstituted solution as this can degrade the peptide [8] .
With bacteriostatic water (0.9% benzyl alcohol), reconstituted L-Carnitine remains usable for 2–4 weeks when refrigerated [8] [13] . Benzyl alcohol suppresses bacterial growth during multi-dose use [6] .
Allow refrigerated vials to reach room temperature before opening to reduce condensation. Inspect solution before each use; discard if discolored or contains precipitates.
Repeated freezing and thawing degrades peptide integrity; aliquot into smaller vials if long-term storage is needed [13] .
Clinical Evidence
Clinical evidence
Well studied in metabolism research for roles in fatty-acid oxidation and exercise physiology.
L-Carnitine has a large, long-standing human and preclinical literature on fatty-acid metabolism, but evidence specific to weight or fat loss in non-deficient individuals is mixed and generally modest, so strong conclusions are not warranted.
- 01L-Carnitine is a naturally occurring amino-acid-derived quaternary ammonium compound essential for transporting long-chain fatty acids into mitochondria for beta-oxidation via the carnitine shuttle (established biochemistry / human physiology).
- 02Human studies of oral L-carnitine intake on body weight and fat mass show small and inconsistent effects; meta-analyses report modest average differences that are heterogeneous across populations (human studies, mixed).
- 03Carnitine status is physiologically relevant in specific deficiency states and certain populations, where it has an established role (human physiology).
- 04Several research forms are studied, including L-carnitine, acetyl-L-carnitine, L-carnitine L-tartrate, and propionyl-L-carnitine, which differ in pharmacokinetics and research use (mechanistic).
- 05Exercise-performance and recovery research shows variable results depending on form, dose, and study design (human studies, mixed).
Evidence maturity varies by compound; much peptide research is preclinical (in vitro or animal-model). Where human data are limited, findings should be read as research observations, not clinical conclusions.
References
Literature references
Published research articles and sources related to L-Carnitine.
- 01Journal of the International Society of Sports Nutrition (2020) — Sawicka AK et al. The bright and the dark sides of L-carnitine supplementation: a systematic review (dose ranges, mechanisms, and metabolic effects) View Sourceet al. (2020)
- 02Clinical Nutrition ESPEN (2020) — Talenezhad N et al. Meta-analysis of 37 RCTs: L-carnitine supplementation yields ~1.2 kg weight loss at ~2,000 mg/day oral dosing with diminishing returns above that dose (PMID: 32359762) View Sourceet al. (2020)
- 03Clinical Pharmacokinetics (2003) — Evans AM & Fornasini G. Pharmacokinetics of L-carnitine: oral bioavailability only 5–18% at high doses (1–6 g) vs. much higher absorption from IV/parenteral routes (PMID: 12908852) View Sourceet al. (2003)
- 04Molecular Nutrition & Food Research (2018) — Zhao Y et al. Subcutaneous L-carnitine bypasses gut bacterial TMAO production and does not promote atherosclerosis in ApoE−/− mice, unlike oral dosing (PMID: 29178259) View Sourceet al. (2018)
- 05American Journal of Kidney Diseases (2001) — Brass EP et al. IV L-carnitine (10–40 mg/kg after dialysis, 3×/week for 24 weeks) increased plasma carnitine, reduced fatigue, preserved exercise capacity in hemodialysis patients with excellent safety profile (PMID: 11325685) View Sourceet al. (2001)
- 06Advances in Therapy (2019) — Usach I et al. Subcutaneous injection review: volumes <0.8 mL minimize pain; room-temperature solutions, benzyl alcohol (vs. m-cresol) reduce pain; abdomen preferred site (PMID: 31529256) View Sourceet al. (2019)
- 07CDC Pink Book (14th Edition) — Vaccine Administration (Chapter 6): subcutaneous injection technique (45–90° angle, no aspiration needed, site selection/rotation) View Source
- 08Drugs.com (2024) — Levocarnitine (Carnitor) dosing: 50 mg/kg IV daily for metabolic disorders; 10–20 mg/kg IV after dialysis for ESRD; doses up to 300 mg/kg/day used safely (medically reviewed Apr 23, 2024) View Sourceet al. (2024)
- 09NIH Office of Dietary Supplements (2022) — Carnitine Health Professional Fact Sheet: high oral doses (>3 g/day) cause fishy odor, nausea; unabsorbed carnitine → gut bacterial TMAO production (potential CV risk) View Sourceet al. (2022)
- 10Linus Pauling Institute, Oregon State University (2022) — L-Carnitine Micronutrient Information Center: FDA-approved uses (dialysis 10–20 mg/kg IV), research summary, safety overview View Sourceet al. (2022)
- 11CDC Vaccine Administration Guidelines — Best practices during vaccination: subcutaneous injection angle (45–90°), site selection, no aspiration needed, rotation to prevent lipohypertrophy View Source
- 12NCBI Bookshelf — Clinical Procedures: Best Practices in Injection Administration (aseptic technique, preparation, sharps disposal) View Source
- 13SB Peptide — Peptide Handling & Storage Guidelines: lyophilized peptides stable for months–years at −20 °C; reconstituted solutions stable 1–2 weeks at 4 °C, longer if frozen in aliquots; avoid freeze–thaw cycles View Source
- 14Pure Lab Peptides — L-Carnitine (200 mg) Product Page: high-purity research peptide with third-party COA documentation View Source
Research Considerations
Research considerations
Research Use Only - not for human or veterinary therapeutic use. A well-characterized endogenous/biochemical compound; on this platform it is handled strictly as a research material. Consult a licensed healthcare professional for any clinical decisions.
Factors noted in the research literature; not patient-specific medical advice.
Regulatory Status
Regulatory status
RUO
Comparisons
Comparisons
| Compound | Mechanism | Route | Status |
|---|---|---|---|
| L-Carnitinethis | An amino acid derivative essential for transporting long-chain fatty acids into mitochondria for beta-oxidation and energy production. | subcutaneous | Investigational / RUO |
| Mazdutide | A long-acting dual agonist of GLP-1 and glucagon receptors, combining GLP-1 appetite/glycemic signaling with glucagon-mediated energy expenditure. | subcutaneous | Investigational / RUO |
| MOTS-C | A 16-amino-acid mitochondrial-derived peptide encoded in the 12S rRNA region of mtDNA that activates AMPK and influences nuclear stress-response gene expression, studied for metabolic homeostasis. | subcutaneous | Investigational / RUO |
| Retatrutide | An investigational triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, combining appetite regulation, insulinotropic activity, and increased energy expenditure. | subcutaneous | Investigational / RUO |
| Semaglutide | Activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite through central mechanisms. | subcutaneous | Investigational / RUO |
| Livagen | A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) studied for peptidase modulation and epigenetic/chromatin effects (e.g., heterochromatin decondensation) in aging cell models. | subcutaneous | Investigational / RUO |
| LL-37 | The sole human cathelicidin-derived cationic antimicrobial peptide (37 residues), studied for broad-spectrum antimicrobial activity, immune modulation, and roles in wound healing and angiogenesis. | subcutaneous | Investigational / RUO |
Attributes shown for research comparison only; not a statement of efficacy or therapeutic equivalence.
FAQ
Frequently asked questions
No. L-carnitine is an amino-acid-derived quaternary ammonium compound, not a peptide. It is included here for its role in fat metabolism.
It functions in the carnitine shuttle, moving long-chain fatty acids into mitochondria for oxidation. This is established cell biology, not a therapeutic claim about weight.
There is extensive human and animal research on carnitine metabolism; however, weight and fat-loss findings in otherwise healthy individuals are inconsistent and typically small.
Yes. Common research forms include L-carnitine, acetyl-L-carnitine, L-carnitine L-tartrate, and propionyl-L-carnitine, which differ in handling and study context.
Carnitine salts are generally stable solids stored cool and dry per the supplier reference. Follow your certificate of analysis and protocol. This is not human-use guidance.
L-carnitine is widely available as a dietary ingredient in many jurisdictions and is also used as a prescription product for specific deficiency states; status varies by country and formulation. On this platform it is referenced for research and education only.
Research-use notice
Research Use Only. This educational content and calculation support is intended for private research documentation. It does not provide medical advice, human-use directions, or claims of safety or effectiveness.